Private Advisor Group’s TG Therapeutics TGTX Stock Holding History

Private Advisor Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,391	Closed	-$370K	–	2572
2025 Q1	$370K	Sell	9,391 -3,050	-25%	-$103K	﹤0.01%	1756
2024 Q4	$374K	Sell	12,441 -1,966	-14%	-$56.4K	﹤0.01%	1739
2024 Q3	$337K	Buy	14,407 +542	+4%	+$11.8K	﹤0.01%	1860
2024 Q2	$247K	Buy	13,865 +292	+2%	+$4.66K	﹤0.01%	2021
2024 Q1	$206K	Sell	13,573 -61	-0.4%	-$972	﹤0.01%	2093
2023 Q4	$233K	Buy	+13,634	New	+$158K	﹤0.01%	1957
2020 Q3	–	Sell	-2,655	Closed	-$52K	–	3233
2020 Q2	$52K	Buy	+2,655	New	+$42.8K	﹤0.01%	2089

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Private Advisor Group's TGTX Position: Q2 2025 in Review

Private Advisor Group sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 9,391 shares — an estimated $370K sold.

Private Advisor Group first reported a position in TGTX in Q2 2020 and held it in 7 quarters. The position peaked at $374K in Q4 2024. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

Private Advisor Group reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
Private Advisor Group sold 9,391 TG Therapeutics shares in Q2 2025, an estimated $370K.
Private Advisor Group first reported a position in TG Therapeutics in Q2 2020 and held it in 7 quarters.
Private Advisor Group's TG Therapeutics position peaked at $374K in Q4 2024.
356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Private Advisor Group's 13F filing for Q2 2025, filed 11 Aug 2025.